Ischemic heart disease Board decisions

The Board granted a 60 percent rating for the Veteran's cardiac disability effective March 8, 2021, and also granted a total disability rating based on individual unemployability due to service-connected disabilities from that date.

The Board denied a compensable disability rating for bilateral hearing loss and an increased rating in excess of 60 percent prior to September 1, 2022, for coronary artery disease.

The Board denied the Veteran's attempts to reopen claims for service connection for prostate cancer, heart condition, and Hepatitis C due to a lack of new and material evidence.

The Board granted service connection for ischemic heart disease, for accrued benefits purposes, but denied the claim for accrued benefits based on the Veteran's non-service-connected diabetes mellitus type II.

The Board granted service connection for hypertension, diabetes mellitus type II (DM II), and coronary artery disease (CAD) due to presumed exposure to herbicide agents during the Veteran's service.

The Board remands the claims for service connection for atrial fibrillation, COPD and anosmia due to an inadequate VA opinion.

The Board granted earlier effective dates for the grant of a 100 percent disability rating for coronary artery disease, basic eligibility to DEA benefits, and SMC based on statutory housebound status, effective August 27, 2019. The appeal for entitlement to TDIU was dismissed as moot.

The appeal was denied for various issues, including service connection and increased disability ratings.

The Veteran withdrew his appeals seeking service connection for a right hip disability, a left hip disability, a thoracolumbar spine disability, cervical strain, and coronary artery disease.

The Board granted an earlier effective date of January 24, 2012, for the grant of service connection for PTSD and a higher initial rating of 70 percent for the Veteran's mental health disability (to include depressive disorder and PTSD), but denied other claims including TDIU, SMC, and higher ratings for migraine headaches and sleep apnea.

The Board denied service connection for a heart disorder, diabetes mellitus, and sleep apnea as the evidence did not support a diagnosis of these conditions during or near to the period on appeal.

The Board granted a 60 percent rating for CAD from April 1, 2019, to November 14, 2021, but denied ratings greater than 60 percent and greater than 30 percent prior to January 30, 2019.

The Veteran is granted special monthly compensation based on the need for regular aid and attendance due to his service-connected major depressive disorder.

The Veteran withdrew his appeal for higher ratings of his service-connected hypertensive heart disease and knee degenerative joint diseases.

The Board denied an initial rating in excess of 30 percent for the Veteran's heart condition based on a METs level greater than 5 but not greater than 7, with symptoms including breathlessness, angina, dizziness, syncope, and arrhythmia.

The veteran withdrew the appeals seeking service connection for various conditions, including skin cancer, diabetes mellitus, and peripheral neuropathy.

The Board granted earlier effective dates of June 24, 2011, for the award of service connection for coronary artery disease, diabetes mellitus, and tremors of both upper extremities.

The Board remands the veteran's claims for service connection for various conditions due to a need for additional evidence.

The Board remands the claims for service connection for left and right wrist carpal tunnel syndrome and compensation under 38 U.S.C. § 1151 for a heart disorder to correct pre-decisional duty to assist errors.

The Board granted service connection for pulmonary hypertension, asthmatic bronchitis condition, centrilobular emphysema with interstitial lung disease and chronic respiratory failure, diabetes mellitus type II as secondary to service-connected pulmonary hypertension, and ischemic heart disease with chronic diastolic congestive heart failure as secondary to service-connected pulmonary hypertension. The claim for obstructive sleep apnea (OSA) was remanded.